The Efficacy Roller Coaster
Monday, January 18, 2021
The temporary results of the Sinovac vaccine’s clinical trials only contain data from 33 percent of participants. There is concern over transparency.
THE 20-page interim report on the third phase of the Sinovac vaccine’s clinical trials was submitted by the University Padjadjaran (Unpad) Medical School’s research team in Bandung, West Java, to Bio Farma on Thursday night, January 7. The report, which was submitted by the Unpad team’s manager, Eddy Fadlyana, and forwarded to the Food and Drug Monitoring Agency (BPOM), was the bases for issuing an emergency use authorizati
...
Subscribe to continue reading.
We craft news with stories.
For the benefits of subscribing to Digital Tempo, See More